CLLS
Cellectis S.A.
Set alert
- YTD
- -77.69%
- 1 year
- -68.97%
- Open
- 1.15
- Prev close
- 1.17
- Mkt cap
- 108.79M
- Vol
- 12.27K
- Avg vol
- 106.07K
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.07
- High
- 1.15
- Forward P/E
- -2.07
- Beta
- 3.20
- Short ratio
- 1.41
- Inst. own
- 16.65%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.88
- 200-d avg
- 2.26
- 1y target
- 6.67
Key statistics
- Market cap
- 157.34M
- Enterprise value
- 94.93M
- Trailing P/E
- 0.00
- Forward P/E
- -2.07
- PEG ratio
- 0.00
- Price / sales
- 4.37
- Price / book
- 1.22
- EPS (TTM)
- -1.16
- Beta
- 3.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -234.39%
- Revenue (TTM)
- 36.04M
- Revenue growth
- 998.00%
- Free cash flow
- -14.38M
- Total cash
- 159.09M
- Total debt
- 89.87M
- Return on equity
- -82.20%
- Shares outstanding
- 100.09M
- Short % of float
- 0.16%
- 50-day average
- 1.88
- 200-day average
- 2.26
Analyst view
Consensus: buy
- Target (low)
- 3.00
- Target (mean)
- 6.67
- Target (high)
- 11.00
- Strong buy2
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.21.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.20 | -0.23 | -0.03 | -15.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.33 | -0.28 | +0.05 | +15.15% |
| May 28, 2024 | Mar 1, 2024 | 0.00 | -0.15 | — | — |
| Apr 29, 2024 | Dec 1, 2023 | 0.00 | -0.64 | — | — |
| Nov 6, 2023 | Sep 1, 2023 | -0.36 | -0.31 | +0.05 | +13.89% |
| Aug 3, 2023 | Jun 1, 2023 | -0.38 | -0.14 | +0.24 | +63.16% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2024 | Barclays | main | Overweight | Overweight |
| Jun 12, 2024 | Oppenheimer | main | Outperform | Outperform |
| May 31, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Nov 1, 2023 | JMP Securities | reit | Market Outperform | Market Outperform |
| Aug 8, 2023 | Oppenheimer | reit | Outperform | Outperform |
| Aug 7, 2023 | JMP Securities | reit | Market Outperform | Market Outperform |
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- cellectis.com
News
- Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
- Cellectis présente de nouvelles données précliniques démontrant une édition efficace du gène APOC3 et une réduction marquée des triglycérides avec .HEAL-101 à l’ESGCT 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
- Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
- Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.
- Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Your note
Sign in to keep a note on CLLS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Long Focus Capital Management, LLC | 6.40% | 4,617,293 | 7.26M | Sep 29, 2024 |
| Capital International Investors | 2.56% | 1,848,804 | 2.91M | Sep 29, 2024 |
| UBS Asset Management Americas Inc | 1.99% | 1,438,255 | 2.26M | Sep 29, 2024 |
| Baillie Gifford and Company | 0.96% | 693,939 | 1.09M | Sep 29, 2024 |
| Principal Financial Group, Inc. | 0.57% | 411,800 | 647.31K | Sep 29, 2024 |
| Macquarie Group Limited | 0.31% | 226,875 | 356.62K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Smallcap World Fund | 2.56% | 1,848,804 | 2.91M | Sep 29, 2024 |
| Principal Small Cap Fund | 0.39% | 284,400 | 447.05K | Jul 30, 2024 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.31% | 226,875 | 356.62K | Sep 29, 2024 |
| Vanguard Whitehall Funds-International Explorer Fund | 0.17% | 122,028 | 191.81K | Jul 30, 2024 |
| JNL Series Trust-JNL/Multi Manager Int'l Small Cap Fund | 0.16% | 116,754 | 183.53K | Sep 29, 2024 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.08% | 58,310 | 91.66K | Aug 30, 2024 |